Back to search

Article

Genetically determining individualized clinical reference ranges for the biomarker tryptase can limit unnecessary procedures and unmask myeloid neoplasms

2022-05-02

Abstract excerpt

<h4>ABSTRACT</h4> Serum tryptase is a biomarker used to aid in the identification of certain myeloid neoplasms, most notably systemic mastocytosis, where baseline (BST) levels >20 ng/mL are a minor criterion for diagnosis. Whereas clonal myeloid neoplasms are rare, the common cause for elevated BST is the genetic trait hereditary alpha-tryptasemia (HαT) caused by increased germline TPSAB1 copy number. To date, the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9c4f42f3-36a8-5b94-8593-be423eec5a80
DOI
10.1101/2022.04.29.22274379
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Genetically determining individualized clinical reference ranges for the biomarker tryptase can limit unnecessary procedures and unmask myeloid neoplasmsDOI 10.1101/2022.04.29.22274379
Select a neighboring publication to make it the new centre.